Skip to content
drillr.ai

WHWK

Whitehawk Therapeutics Inc

NASDAQ · USHealthcareBiotechnology
$3.79-2.57%

Price as of Jul 20, 2026

WHWK news

Whitehawk Therapeutics Inc news

A server-rendered, paginated timeline of the latest available company news.

  1. Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

    Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026 PR Newswire MORRISTOWN, N.J., May 30, 2026 SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, w

    PR Newswire ·

  2. Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

    Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload PR Newswire MORRISTOWN, N.J., May 21, 2026 Agreement with Hangzhou DAC Provides Option for Up to Five New, Internally Developed ADC Programs, Including Dual-Payload Variations Hangzhou DAC's DXC006 Data at ASCO Reinforce Conviction for CPT113, a Core Technology of Whitehawk's ADC Platform Phase 1 Dose-Escalation Trials of HWK-007 and HWK-016 are Currently Enrolling; HWK-007 Trials-in-Progr

    PR Newswire ·

  3. Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

    Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum PR Newswire MORRISTOWN, N.J., May 15, 2026 MORRISTOWN, N.J., May 15, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will participate in a virtual firesi

    PR Newswire ·

  4. Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing

    Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing PR Newswire MORRISTOWN, N.J., May 13, 2026 MORRISTOWN, N.J., May 13, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (the "Company" or "Whitehawk") (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that it has entered into a securities purchase agree

    PR Newswire ·

  5. Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026

    Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 PR Newswire MORRISTOWN, N.J., March 17, 2026 MORRISTOWN, N.J., March 17, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced it will pres

    PR Newswire ·